Results for Pancreatectomy

Share:
1 - 10 of 12
N. Scott Adzick, MD, MMM, FACS, FAAP
N. Scott Adzick

The founder and director of CHOP's Center for Fetal Diagnosis and Treatment, Dr. Adzick is an innovator in the field of fetal medicine, pursuing groundbreaking prenatal treatment for debilitating birth defects. He led the NIH-funded "Management of Myelomeningocele Study" (MOMS) at CHOP, a breakthrough research program that showed fetal surgery for spina bifida results in significantly improved outcomes.

E-mail:
adzick [at] chop.edu

Snapshot Science: Can Exendin-(9-39) Treat Congenital HI in Children?

Published on
Apr 13, 2022
in Cornerstone Blog
Can Exendin-(9-39) Treat Congenital HI in Children?
New evidence from CHOP researchers supports the use of exendin-(9-39) as an effective treatment for children with HI.

In the News: AHA Award, Human Cell Atlas, Bihormonal Bionic Pancreas, Autism in School

Published on
Sep 17, 2021
in Cornerstone Blog
In the News: Celebrate an American Heart Association Award and More
This week’s In the News highlights

Advancing Personalized Hyperinsulinism Treatment Through Discovery

Published on
Dec 20, 2019
in Cornerstone Blog
Dr. De León-Crutchlow talks with a patient.
A new Frontier Program offers families hope backed by the experience of treating hundreds of cases of congenital hyperinsulinism.

In the News: Birth Defects Awareness, Million Dollar Bike Ride Grant, WAO Center of Excellence, Alopecia and Thyroid Screening, New PolicyLab Video

Published on
Jan 12, 2018
in Cornerstone Blog
CHOP Research In the News
It's a brand-new year for breakthroughs at Children's Hospital of Philadelphia Research Institute. Here are the first headlines of 2018.

CHOP Doctor Awarded the CHI "Be My Sugar" Award for Medical Excellence

Published on
Nov 22, 2017
in Press Releases
As a pediatric endocrinologist and director of the Congenital Hyperinsulinism Center at Children's Hospital of Philadelphia (CHOP), Diva De León-Crutchlow, MD, specializes in the diagnosis and management of hyperinsulinism (HI) and other hypoglycemia disorders.

CHOP Surgeon-in-Chief N. Scott Adzick, MD, MMM, FACS, FAAP, Recognized by Congenital Hyperinsulinism International (CHI)

Published on
Nov 8, 2016
in Press Releases
Awarded the CHI “Be My Sugar” Award for Surgical Excellence

Blood Sugar Stability in Individuals with Hyperinsulinism

The purpose of the study is to evaluate blood sugar levels and beta-cell function in adolescents and adult with KATP hyperinsulinism whom did not undergo pancreatectomy.

Dasiglucagon for the Treatment of Children with Congenital Hyperinsulinism

This study is a 2 period, open label study that will evaluate the safety and efficacy of dasiglucagon in children between the ages of 3 months and 12 years.

Advancement of Hyperinsulinism Care and Research

Advancement of Hyperinsulinism Care and Research

Revolutionizing our understanding of the genetic causes and mechanisms of hyperinsulinism, developing diagnostic tools for a precision-medicine approach to treatment, and discovering new treatment options.

1 - 10 of 12